
Grail's stock jumps 55% after positive FDA advisory vote on Galleri cancer test.
Grail's stock surged 55% in one week following a positive FDA advisory committee vote on its Galleri multi-cancer early detection test, which was deemed safe and beneficial. Analyst Kyle Mikson raised the price target from $80 to $150, reflecting str...





